Patent: 9,657,310
✉ Email this page to a colleague
Summary for Patent: 9,657,310
| Title: | Expression vector |
| Abstract: | Disclosed are a novel expression vector for efficient expression of recombinant proteins in mammalian cells, a mammalian cell transformed with the vector, and a method for production of the mammalian cell. The expression vector is an expression vector for expression of a mammalian protein and includes a gene expression regulatory site, and a gene encoding the protein downstream thereof, and an internal ribosome entry site further downstream thereof, and a gene encoding a glutamine synthetase further downstream thereof, and a dihydrofolate reductase gene downstream of either the same gene expression regulatory site or another gene expression regulatory site in addition to the former. |
| Inventor(s): | Takahashi; Kenichi (Hyogo, JP), Kakimoto; Shinji (Hyogo, JP) |
| Assignee: | JCR PHARMACEUTICALS CO., LTD. (Ashiya-Shi, Hyogo, JP) |
| Application Number: | 14/396,929 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,657,310
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Biomarin Pharmaceutical Inc. | NAGLAZYME | galsulfase | Injection | 125117 | 05/31/2005 | ⤷ Try a Trial | 2032-04-27 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
